Table 2. Demographic characteristics of the study subjects (n=897).
| Variable | No. (%) |
|---|---|
| Age (yr)* | 57.1 ± 5.7 |
| Estrogen receptor status | |
| Positive | 849 (94.6) |
| Negative | 48 (5.4) |
| Progesterone receptor status | |
| Positive | 757 (84.4) |
| Negative | 140 (15.6) |
| Stage | |
| I | 410 (45.7) |
| II | 396 (44.1) |
| III | 91 (10.2) |
| Tumor size | |
| T1 | 533 (59.4 ) |
| T2 | 330 (36.8) |
| T3 | 34 (3.8) |
| Axillary lymph node metastasis | |
| N0 | 575 (64.1) |
| N1 | 225 (25.1) |
| N2 | 64 (7.1) |
| N3 | 33 (3.7) |
| Adjuvant treatment | |
| Radiation treatment | 598 (66.7) |
| Chemotherapy | 684 (76.3) |
| Operative method | |
| Modified radical mastectomy | 379 (42.3) |
| Breast-conserving surgery | 518 (57.7) |
| Types of adjuvant chemotherapy | |
| Anthracycline-based treatment | |
| Yes | 468 (68.4) |
| No | 216 (31.6) |
| Taxane-based treatment | |
| Yes | 251 (36.7) |
| No | 487 (63.3) |
| Bone mineral density* | |
| Femur | −0.21 ± 1.07 |
| Spine | −0.44 ± 1.16 |
*Mean±SD.